Vinblastine

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Cytostatic drug, vinca alkaloid which is semi-synthetically extracted like vincristine from vinca rosea, an evergreen species.

Half-life
This section has been translated automatically.

25 h

Pharmacodynamics (Effect)
This section has been translated automatically.

Inhibition of intracellular tubulin synthesis. Arrest of the cells in the metaphase of mitosis. Disruption of DNA and RNA synthesis. Induction of apoptosis.

Indication
This section has been translated automatically.

M. Hodgkin, mycosis fungoides, testicular carcinoma, malignant melanoma, Kaposi's sarcoma.

Notice! During the therapy and up to 6 months afterwards, effective contraception must be carried out.

Dosage and method of use
This section has been translated automatically.

3.7 mg/m2 KO/day i.v. every 1-2 weeks or in polychemotherapy 6-8 mg/m2 KO/day for 1-2 days every 3-4 weeks.

Undesirable effects
This section has been translated automatically.

BB changes, gastrointestinal disorders, subileus, liver or kidney damage, hyperuricemia, alopecia (see Alopecia medicamentosa), dermatitis, stomatitis, erythroderma, neurotoxic disorders, disorders of spermiogenesis and ovulation. Very rarely respiratory distress or respiratory disorders.

Interactions
This section has been translated automatically.

The administration of myelotoxic substances increases bone marrow toxicity and the blood sugar-lowering effect of oral antidiabetics is enhanced.

Contraindication
This section has been translated automatically.

Pregnancy, lactation, acute infections, severe bone marrow depression.

Preparations
This section has been translated automatically.

Vinblastine 10 Hexal

Authors

Last updated on: 29.10.2020